Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial)

被引：2
|
作者：
Garufi, C. [1 ]
Torsello, A. [1 ]
Tumolo, S. [2 ]
Mottolese, M. [1 ]
Melucci, E. [1 ]
Campanella, C. [1 ]
Zeuli, M. [1 ]
Sperduti, I. [1 ]
Ettorre, G. M. [3 ]
Cognetti, F. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Rome, Italy
[2] Osped SM Angeli, Pordenone, Italy
[3] Osped S Camillo Roma, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71181-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：348 / 348
页数：1
相关论文
共 50 条
  • [31] A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma
    Kalofonos, HP
    Skarlos, D
    Bafaloukos, D
    Papakostas, P
    Bamias, A
    Janinis, J
    Timotheadou, E
    Kouvatseas, G
    Stavropoulos, M
    Economopulos, T
    Fountzilas, G
    CANCER INVESTIGATION, 2003, 21 (06) : 855 - 862
  • [32] Biweekly administration of irinotecan (CPT-11), oxaliplatin (OX) and 5-fluorouracil (5-FU) as first-line treatment of advanced or metastatic colorectal cancer (MCRC)
    Reina, JJ
    Sánchez-Rovira, P
    Bernabé, R
    Bolaños, M
    González, E
    Belón, J
    Gómez-Reina, MJ
    Gallurt, P
    Moreno-Nogueira, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 260S - 260S
  • [33] Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan
    Tai, CJ
    Liu, JH
    Chen, WS
    Lin, JK
    Wang, WS
    Yen, CC
    Chiou, TJ
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 136 - 140
  • [34] Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11-or OHP-based CHT.
    Mini, E
    Nobili, S
    Del Buono, S
    Mazzocchi, V
    Filippelli, F
    Giglioni, B
    Mazzei, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 306S - 306S
  • [35] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [36] A dose finding study of biweekly administration of irinotecan (CPT-11), 5-fluorouracil (5-FU) and levofolinic acid (I-LV) in colorectal cancer
    Casaretti, R
    Catalano, G
    Comella, P
    De Vita, F
    Avallone, V
    Gravina, A
    Orditura, M
    Comis, S
    Faranda, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [37] A bi-weekly schedule of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in advanced colorectal cancer (ACRC): Phase I study.
    Morese, R
    Ricevuto, U
    Cannita, K
    Antonini, CGC
    Lanfiuti, BP
    Trapasso, T
    Porzio, G
    Marchetti, P
    Ficorella, C
    ANNALS OF ONCOLOGY, 2000, 11 : 71 - 71
  • [38] Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial
    Maiello, E
    Giuliani, F
    Gebbia, V
    Cigolari, S
    Fortunato, S
    Paoletti, G
    Borsellino, N
    Lopez, M
    Gebbia, N
    Colucci, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
  • [39] CPT-11/L-OHP/LV5FU combination (FOLFIRINOX) as an induction chemotherapy (CT) in patients (pts) with previously unresectable liver metastases from colorectal cancer (LMCRC): efficacy and tolerance of a prospective phase II trial
    Ychou, Marc
    Rougier, Philippe
    Desseigne, Francoise
    Negrier, Sylvie
    Viret, Frederic
    Bugat, Roland
    Guimbaud, Rosine
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 73
  • [40] Phase I-II study of bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hrs continuous infusion in advanced colorectal cancer.
    Masi, G
    Falcone, A
    Allegrini, G
    Lencioni, M
    Pfanner, E
    Brunetti, I
    Galli, C
    Di Marsico, R
    Antonuzzo, A
    Conte, PF
    ANNALS OF ONCOLOGY, 2000, 11 : 70 - 70
12345